{"nctId":"NCT00835770","briefTitle":"BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)","startDateStruct":{"date":"2009-02-03","type":"ACTUAL"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"count":1736,"armGroups":[{"label":"BG00012 plus placebo","type":"EXPERIMENTAL","interventionNames":["Drug: dimethyl fumarate","Drug: Placebo"]},{"label":"BG00012","type":"EXPERIMENTAL","interventionNames":["Drug: dimethyl fumarate"]}],"interventions":[{"name":"dimethyl fumarate","otherNames":["BG00012","Tecfidera","DMF"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).\n\nKey Exclusion Criteria:\n\n* Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.\n* Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.\n* Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"58 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"824","spread":null},{"groupId":"OG001","value":"814","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Had Relapses","description":"Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"34","spread":null},{"groupId":"OG003","value":"36","spread":null},{"groupId":"OG004","value":"31","spread":null},{"groupId":"OG005","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate (ARR)","description":"The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.159","spread":null},{"groupId":"OG001","value":"0.179","spread":null},{"groupId":"OG002","value":"0.200","spread":null},{"groupId":"OG003","value":"0.199","spread":null},{"groupId":"OG004","value":"0.184","spread":null},{"groupId":"OG005","value":"0.212","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384","description":"EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":"1.251"},{"groupId":"OG001","value":"2.43","spread":"1.144"},{"groupId":"OG002","value":"2.50","spread":"1.135"},{"groupId":"OG003","value":"2.54","spread":"1.218"},{"groupId":"OG004","value":"2.57","spread":"1.249"},{"groupId":"OG005","value":"2.68","spread":"1.231"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"1.160"},{"groupId":"OG001","value":"0.26","spread":"1.213"},{"groupId":"OG002","value":"0.37","spread":"1.328"},{"groupId":"OG003","value":"0.53","spread":"1.278"},{"groupId":"OG004","value":"0.39","spread":"1.217"},{"groupId":"OG005","value":"0.49","spread":"1.319"}]}]}]},{"type":"SECONDARY","title":"Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The Gd-enhancing lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.87"},{"groupId":"OG001","value":"0.4","spread":"1.29"},{"groupId":"OG002","value":"0.2","spread":"0.66"},{"groupId":"OG003","value":"0.3","spread":"1.14"},{"groupId":"OG004","value":"0.5","spread":"1.19"},{"groupId":"OG005","value":"0.4","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.77"},{"groupId":"OG001","value":"0.4","spread":"1.28"},{"groupId":"OG002","value":"0.1","spread":"0.38"},{"groupId":"OG003","value":"0.2","spread":"0.82"},{"groupId":"OG004","value":"0.6","spread":"1.33"},{"groupId":"OG005","value":"0.3","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.66"},{"groupId":"OG001","value":"0.4","spread":"1.30"},{"groupId":"OG002","value":"0.2","spread":"0.44"},{"groupId":"OG003","value":"0.1","spread":"0.29"},{"groupId":"OG004","value":"0.5","spread":"2.48"},{"groupId":"OG005","value":"0.3","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.02"},{"groupId":"OG001","value":"0.5","spread":"1.85"},{"groupId":"OG002","value":"0.5","spread":"1.72"},{"groupId":"OG003","value":"0.3","spread":"0.96"},{"groupId":"OG004","value":"0.2","spread":"0.60"},{"groupId":"OG005","value":"0.6","spread":"2.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"3.14"},{"groupId":"OG001","value":"0.5","spread":"2.29"},{"groupId":"OG002","value":"0.2","spread":"0.50"},{"groupId":"OG003","value":"0.2","spread":"0.51"},{"groupId":"OG004","value":"0.2","spread":"0.58"},{"groupId":"OG005","value":"0.3","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.74"},{"groupId":"OG001","value":"0.5","spread":"1.81"},{"groupId":"OG002","value":"0.1","spread":"0.40"},{"groupId":"OG003","value":"0.7","spread":"2.76"},{"groupId":"OG004","value":"0.0","spread":"0.00"},{"groupId":"OG005","value":"0.3","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The Gd-enhancing lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":"179.28"},{"groupId":"OG001","value":"48.6","spread":"205.43"},{"groupId":"OG002","value":"96.0","spread":"260.79"},{"groupId":"OG003","value":"142.5","spread":"459.76"},{"groupId":"OG004","value":"37.1","spread":"138.82"},{"groupId":"OG005","value":"41.7","spread":"116.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"526.51"},{"groupId":"OG001","value":"70.0","spread":"366.63"},{"groupId":"OG002","value":"18.8","spread":"91.47"},{"groupId":"OG003","value":"25.3","spread":"108.19"},{"groupId":"OG004","value":"42.5","spread":"123.67"},{"groupId":"OG005","value":"42.7","spread":"148.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":"245.14"},{"groupId":"OG001","value":"56.1","spread":"271.29"},{"groupId":"OG002","value":"27.7","spread":"204.80"},{"groupId":"OG003","value":"13.3","spread":"67.01"},{"groupId":"OG004","value":"64.3","spread":"183.16"},{"groupId":"OG005","value":"22.3","spread":"60.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":"291.14"},{"groupId":"OG001","value":"47.0","spread":"169.68"},{"groupId":"OG002","value":"18.8","spread":"66.15"},{"groupId":"OG003","value":"3.8","spread":"25.03"},{"groupId":"OG004","value":"42.6","spread":"142.55"},{"groupId":"OG005","value":"92.9","spread":"397.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":"217.89"},{"groupId":"OG001","value":"54.5","spread":"251.31"},{"groupId":"OG002","value":"45.8","spread":"156.88"},{"groupId":"OG003","value":"19.9","spread":"79.19"},{"groupId":"OG004","value":"12.0","spread":"40.56"},{"groupId":"OG005","value":"55.1","spread":"169.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":"650.06"},{"groupId":"OG001","value":"69.3","spread":"374.67"},{"groupId":"OG002","value":"21.7","spread":"77.87"},{"groupId":"OG003","value":"14.1","spread":"45.22"},{"groupId":"OG004","value":"17.5","spread":"46.19"},{"groupId":"OG005","value":"17.1","spread":"48.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":"93.28"},{"groupId":"OG001","value":"53.1","spread":"250.87"},{"groupId":"OG002","value":"7.9","spread":"30.09"},{"groupId":"OG003","value":"230.2","spread":"1092.11"},{"groupId":"OG004","value":"0.0","spread":"0.00"},{"groupId":"OG005","value":"34.1","spread":"102.87"}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The T2 lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"4.07"},{"groupId":"OG001","value":"2.2","spread":"6.15"},{"groupId":"OG002","value":"2.7","spread":"4.96"},{"groupId":"OG003","value":"2.4","spread":"5.45"},{"groupId":"OG004","value":"3.4","spread":"6.57"},{"groupId":"OG005","value":"2.1","spread":"3.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"8.35"},{"groupId":"OG001","value":"4.1","spread":"10.01"},{"groupId":"OG002","value":"3.8","spread":"7.24"},{"groupId":"OG003","value":"2.9","spread":"6.78"},{"groupId":"OG004","value":"4.9","spread":"8.51"},{"groupId":"OG005","value":"3.4","spread":"5.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"9.81"},{"groupId":"OG001","value":"5.2","spread":"10.01"},{"groupId":"OG002","value":"4.0","spread":"7.27"},{"groupId":"OG003","value":"4.3","spread":"10.12"},{"groupId":"OG004","value":"5.7","spread":"9.45"},{"groupId":"OG005","value":"5.2","spread":"9.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"14.04"},{"groupId":"OG001","value":"7.5","spread":"15.14"},{"groupId":"OG002","value":"5.6","spread":"10.09"},{"groupId":"OG003","value":"5.6","spread":"14.19"},{"groupId":"OG004","value":"5.5","spread":"9.94"},{"groupId":"OG005","value":"5.6","spread":"13.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"17.09"},{"groupId":"OG001","value":"9.5","spread":"20.33"},{"groupId":"OG002","value":"8.2","spread":"14.87"},{"groupId":"OG003","value":"7.7","spread":"17.89"},{"groupId":"OG004","value":"6.8","spread":"11.74"},{"groupId":"OG005","value":"7.5","spread":"16.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"18.53"},{"groupId":"OG001","value":"12.4","spread":"28.23"},{"groupId":"OG002","value":"7.5","spread":"13.89"},{"groupId":"OG003","value":"10.4","spread":"22.05"},{"groupId":"OG004","value":"8.9","spread":"15.04"},{"groupId":"OG005","value":"6.0","spread":"8.90"}]}]}]},{"type":"SECONDARY","title":"Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The T2 lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10231.9","spread":"11214.17"},{"groupId":"OG001","value":"10408.3","spread":"12166.80"},{"groupId":"OG002","value":"8883.7","spread":"8570.10"},{"groupId":"OG003","value":"10806.3","spread":"12060.05"},{"groupId":"OG004","value":"12628.9","spread":"11258.69"},{"groupId":"OG005","value":"13044.4","spread":"14608.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9951.9","spread":"10750.15"},{"groupId":"OG001","value":"9849.6","spread":"10986.36"},{"groupId":"OG002","value":"8992.1","spread":"7952.13"},{"groupId":"OG003","value":"10114.5","spread":"10121.61"},{"groupId":"OG004","value":"11160.7","spread":"9565.55"},{"groupId":"OG005","value":"12979.0","spread":"14415.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10331.3","spread":"11359.81"},{"groupId":"OG001","value":"10434.0","spread":"12201.38"},{"groupId":"OG002","value":"8645.2","spread":"7787.60"},{"groupId":"OG003","value":"9985.7","spread":"10715.73"},{"groupId":"OG004","value":"11318.1","spread":"9873.73"},{"groupId":"OG005","value":"13974.1","spread":"15432.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9930.1","spread":"10686.26"},{"groupId":"OG001","value":"10280.7","spread":"11324.58"},{"groupId":"OG002","value":"8829.4","spread":"7482.93"},{"groupId":"OG003","value":"9792.3","spread":"9842.28"},{"groupId":"OG004","value":"10188.5","spread":"8064.09"},{"groupId":"OG005","value":"12949.7","spread":"14036.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9837.7","spread":"10845.04"},{"groupId":"OG001","value":"10760.0","spread":"11987.16"},{"groupId":"OG002","value":"9077.6","spread":"7794.52"},{"groupId":"OG003","value":"10576.3","spread":"12029.26"},{"groupId":"OG004","value":"10421.9","spread":"8773.41"},{"groupId":"OG005","value":"11671.5","spread":"13124.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10611.2","spread":"11633.95"},{"groupId":"OG001","value":"11087.5","spread":"12464.90"},{"groupId":"OG002","value":"9711.1","spread":"8709.46"},{"groupId":"OG003","value":"10591.4","spread":"11613.26"},{"groupId":"OG004","value":"11009.9","spread":"9551.94"},{"groupId":"OG005","value":"12254.4","spread":"13732.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9611.8","spread":"9447.18"},{"groupId":"OG001","value":"9800.8","spread":"11279.84"},{"groupId":"OG002","value":"8819.8","spread":"8866.90"},{"groupId":"OG003","value":"10537.6","spread":"10684.47"},{"groupId":"OG004","value":"11586.3","spread":"9728.19"},{"groupId":"OG005","value":"10404.8","spread":"12245.75"}]}]}]},{"type":"SECONDARY","title":"Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The T1 hypointense lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"2.13"},{"groupId":"OG001","value":"1.0","spread":"2.37"},{"groupId":"OG002","value":"1.8","spread":"3.81"},{"groupId":"OG003","value":"1.7","spread":"3.71"},{"groupId":"OG004","value":"2.0","spread":"4.22"},{"groupId":"OG005","value":"1.3","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"3.63"},{"groupId":"OG001","value":"1.9","spread":"3.91"},{"groupId":"OG002","value":"1.8","spread":"3.33"},{"groupId":"OG003","value":"2.1","spread":"5.00"},{"groupId":"OG004","value":"3.0","spread":"5.85"},{"groupId":"OG005","value":"1.9","spread":"3.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"4.61"},{"groupId":"OG001","value":"2.8","spread":"5.19"},{"groupId":"OG002","value":"2.0","spread":"3.69"},{"groupId":"OG003","value":"2.6","spread":"7.02"},{"groupId":"OG004","value":"3.1","spread":"6.20"},{"groupId":"OG005","value":"2.9","spread":"5.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"7.03"},{"groupId":"OG001","value":"3.4","spread":"6.79"},{"groupId":"OG002","value":"2.9","spread":"5.12"},{"groupId":"OG003","value":"3.8","spread":"10.71"},{"groupId":"OG004","value":"3.3","spread":"6.74"},{"groupId":"OG005","value":"3.0","spread":"7.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"8.25"},{"groupId":"OG001","value":"4.8","spread":"9.39"},{"groupId":"OG002","value":"4.0","spread":"7.52"},{"groupId":"OG003","value":"4.9","spread":"13.30"},{"groupId":"OG004","value":"4.0","spread":"8.06"},{"groupId":"OG005","value":"4.2","spread":"10.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"5.72"},{"groupId":"OG001","value":"5.9","spread":"12.02"},{"groupId":"OG002","value":"4.5","spread":"7.38"},{"groupId":"OG003","value":"3.6","spread":"4.51"},{"groupId":"OG004","value":"1.0","spread":"1.10"},{"groupId":"OG005","value":"5.6","spread":"6.81"}]}]}]},{"type":"SECONDARY","title":"Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)","description":"The T1 hypointense lesions was evaluated using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3640.1","spread":"5598.31"},{"groupId":"OG001","value":"3447.3","spread":"4900.96"},{"groupId":"OG002","value":"2754.2","spread":"3552.30"},{"groupId":"OG003","value":"3623.1","spread":"5549.13"},{"groupId":"OG004","value":"3204.3","spread":"4221.55"},{"groupId":"OG005","value":"3572.6","spread":"4915.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3829.5","spread":"5824.26"},{"groupId":"OG001","value":"3715.5","spread":"5112.21"},{"groupId":"OG002","value":"2891.9","spread":"3034.00"},{"groupId":"OG003","value":"3936.0","spread":"5271.89"},{"groupId":"OG004","value":"3271.0","spread":"4157.24"},{"groupId":"OG005","value":"3743.3","spread":"5374.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3841.2","spread":"5682.74"},{"groupId":"OG001","value":"3853.7","spread":"5428.66"},{"groupId":"OG002","value":"2921.0","spread":"3327.93"},{"groupId":"OG003","value":"3849.4","spread":"5167.13"},{"groupId":"OG004","value":"3510.4","spread":"4672.80"},{"groupId":"OG005","value":"3949.7","spread":"5018.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3767.4","spread":"4969.23"},{"groupId":"OG001","value":"4074.0","spread":"5413.85"},{"groupId":"OG002","value":"3145.6","spread":"3366.27"},{"groupId":"OG003","value":"4006.9","spread":"5062.08"},{"groupId":"OG004","value":"3499.2","spread":"4198.50"},{"groupId":"OG005","value":"4126.1","spread":"5695.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3834.9","spread":"4942.19"},{"groupId":"OG001","value":"4177.4","spread":"5301.68"},{"groupId":"OG002","value":"3385.4","spread":"3575.44"},{"groupId":"OG003","value":"4330.0","spread":"5136.67"},{"groupId":"OG004","value":"3592.0","spread":"4069.39"},{"groupId":"OG005","value":"4089.3","spread":"4996.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4038.6","spread":"5145.85"},{"groupId":"OG001","value":"4238.2","spread":"5248.84"},{"groupId":"OG002","value":"3406.4","spread":"3936.73"},{"groupId":"OG003","value":"3823.9","spread":"4274.82"},{"groupId":"OG004","value":"3503.4","spread":"3933.75"},{"groupId":"OG005","value":"4057.7","spread":"5223.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3603.3","spread":"4394.60"},{"groupId":"OG001","value":"3973.1","spread":"5202.05"},{"groupId":"OG002","value":"3350.6","spread":"4140.34"},{"groupId":"OG003","value":"4187.5","spread":"4835.43"},{"groupId":"OG004","value":"3264.9","spread":"3639.91"},{"groupId":"OG005","value":"2959.1","spread":"3918.62"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Brain Atrophy","description":"Brain atrophy was measured using magnetic resonance imaging (MRI) technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.206","spread":"1.1006"},{"groupId":"OG001","value":"-1.263","spread":"1.0848"},{"groupId":"OG002","value":"-1.487","spread":"1.3086"},{"groupId":"OG003","value":"-1.320","spread":"1.4021"},{"groupId":"OG004","value":"-1.496","spread":"1.1316"},{"groupId":"OG005","value":"-1.414","spread":"1.1882"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.372","spread":"1.1382"},{"groupId":"OG001","value":"-1.500","spread":"1.0893"},{"groupId":"OG002","value":"-1.589","spread":"1.3630"},{"groupId":"OG003","value":"-1.775","spread":"1.7191"},{"groupId":"OG004","value":"-1.883","spread":"1.2383"},{"groupId":"OG005","value":"-1.810","spread":"1.4556"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.708","spread":"1.4109"},{"groupId":"OG001","value":"-1.876","spread":"1.2604"},{"groupId":"OG002","value":"-2.139","spread":"1.5884"},{"groupId":"OG003","value":"-2.353","spread":"1.7897"},{"groupId":"OG004","value":"-2.386","spread":"1.3168"},{"groupId":"OG005","value":"-2.252","spread":"2.2124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.138","spread":"1.6831"},{"groupId":"OG001","value":"-2.117","spread":"1.4000"},{"groupId":"OG002","value":"-2.230","spread":"1.7755"},{"groupId":"OG003","value":"-2.476","spread":"1.7062"},{"groupId":"OG004","value":"-2.645","spread":"1.2284"},{"groupId":"OG005","value":"-2.417","spread":"2.0486"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.313","spread":"1.6309"},{"groupId":"OG001","value":"-2.253","spread":"1.3721"},{"groupId":"OG002","value":"-2.271","spread":"1.4817"},{"groupId":"OG003","value":"-2.593","spread":"1.9043"},{"groupId":"OG004","value":"-2.249","spread":"1.2985"},{"groupId":"OG005","value":"-2.790","spread":"2.2188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.216","spread":"1.5744"},{"groupId":"OG001","value":"-2.271","spread":"1.2193"},{"groupId":"OG002","value":"-2.470","spread":"1.6757"},{"groupId":"OG003","value":"-2.849","spread":"1.9648"},{"groupId":"OG004","value":"-2.657","spread":"1.7051"},{"groupId":"OG005","value":"-2.496","spread":"1.3699"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Magnetization Transfer Ratio (MTR)","description":"Magnetization Transfer Ratio (MTR) was measured using MRI technique.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.325","spread":"5.4932"},{"groupId":"OG001","value":"-0.383","spread":"4.8621"},{"groupId":"OG002","value":"1.034","spread":"7.3548"},{"groupId":"OG003","value":"-0.567","spread":"4.4766"},{"groupId":"OG004","value":"-0.081","spread":"13.6416"},{"groupId":"OG005","value":"-0.334","spread":"1.5103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.427","spread":"6.6493"},{"groupId":"OG001","value":"-0.532","spread":"4.9880"},{"groupId":"OG002","value":"1.630","spread":"7.6584"},{"groupId":"OG003","value":"-0.947","spread":"7.0771"},{"groupId":"OG004","value":"-4.269","spread":"12.6065"},{"groupId":"OG005","value":"0.215","spread":"1.4270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.042","spread":"9.2548"},{"groupId":"OG001","value":"0.509","spread":"7.2692"},{"groupId":"OG002","value":"1.525","spread":"8.6421"},{"groupId":"OG003","value":"1.411","spread":"12.2825"},{"groupId":"OG004","value":"-4.460","spread":"10.3887"},{"groupId":"OG005","value":"3.119","spread":"8.1676"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.038","spread":"10.8680"},{"groupId":"OG001","value":"0.955","spread":"8.6105"},{"groupId":"OG002","value":"3.012","spread":"9.3831"},{"groupId":"OG003","value":"3.103","spread":"13.0046"},{"groupId":"OG004","value":"1.384","spread":"15.7611"},{"groupId":"OG005","value":"3.841","spread":"10.8600"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"15.6190"},{"groupId":"OG001","value":"1.647","spread":"8.3094"},{"groupId":"OG002","value":"3.213","spread":"9.6621"},{"groupId":"OG003","value":"4.108","spread":"13.8103"},{"groupId":"OG004","value":"2.959","spread":"16.8386"},{"groupId":"OG005","value":"0.673","spread":"25.9962"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"4.0206"},{"groupId":"OG001","value":"-0.391","spread":"4.6415"},{"groupId":"OG002","value":"-0.666","spread":"2.0741"},{"groupId":"OG003","value":"-0.622","spread":"2.2922"},{"groupId":"OG004","value":"-0.466","spread":"0.9410"},{"groupId":"OG005","value":"-1.114","spread":"2.4539"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384","description":"The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.48","spread":"25.938"},{"groupId":"OG001","value":"71.78","spread":"24.849"},{"groupId":"OG002","value":"69.67","spread":"24.481"},{"groupId":"OG003","value":"67.97","spread":"26.279"},{"groupId":"OG004","value":"69.10","spread":"25.226"},{"groupId":"OG005","value":"68.20","spread":"25.370"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"21.972"},{"groupId":"OG001","value":"-4.79","spread":"24.641"},{"groupId":"OG002","value":"-7.37","spread":"22.253"},{"groupId":"OG003","value":"-6.89","spread":"23.194"},{"groupId":"OG004","value":"-6.19","spread":"21.719"},{"groupId":"OG005","value":"-6.25","spread":"28.350"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.46","spread":"41.254"},{"groupId":"OG001","value":"58.42","spread":"41.280"},{"groupId":"OG002","value":"56.35","spread":"40.896"},{"groupId":"OG003","value":"59.87","spread":"41.747"},{"groupId":"OG004","value":"55.26","spread":"40.390"},{"groupId":"OG005","value":"53.57","spread":"42.029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.20","spread":"48.259"},{"groupId":"OG001","value":"-2.75","spread":"47.283"},{"groupId":"OG002","value":"-10.00","spread":"43.188"},{"groupId":"OG003","value":"-8.24","spread":"53.177"},{"groupId":"OG004","value":"-12.21","spread":"40.595"},{"groupId":"OG005","value":"-1.04","spread":"54.568"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.68","spread":"25.587"},{"groupId":"OG001","value":"70.42","spread":"24.688"},{"groupId":"OG002","value":"68.51","spread":"26.163"},{"groupId":"OG003","value":"69.44","spread":"26.016"},{"groupId":"OG004","value":"69.30","spread":"25.766"},{"groupId":"OG005","value":"68.59","spread":"26.102"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"28.525"},{"groupId":"OG001","value":"-1.47","spread":"25.779"},{"groupId":"OG002","value":"-2.92","spread":"23.486"},{"groupId":"OG003","value":"-4.36","spread":"25.935"},{"groupId":"OG004","value":"-3.60","spread":"22.138"},{"groupId":"OG005","value":"-4.46","spread":"33.297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.99","spread":"21.563"},{"groupId":"OG001","value":"55.44","spread":"20.768"},{"groupId":"OG002","value":"54.45","spread":"18.690"},{"groupId":"OG003","value":"52.42","spread":"20.028"},{"groupId":"OG004","value":"51.21","spread":"18.707"},{"groupId":"OG005","value":"52.58","spread":"19.675"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"18.744"},{"groupId":"OG001","value":"-2.12","spread":"20.595"},{"groupId":"OG002","value":"-2.28","spread":"16.752"},{"groupId":"OG003","value":"-0.52","spread":"22.035"},{"groupId":"OG004","value":"-5.64","spread":"18.270"},{"groupId":"OG005","value":"1.21","spread":"21.674"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.48","spread":"20.966"},{"groupId":"OG001","value":"52.21","spread":"19.842"},{"groupId":"OG002","value":"50.63","spread":"19.130"},{"groupId":"OG003","value":"50.64","spread":"21.069"},{"groupId":"OG004","value":"51.30","spread":"19.703"},{"groupId":"OG005","value":"50.33","spread":"20.019"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"19.857"},{"groupId":"OG001","value":"-0.73","spread":"19.033"},{"groupId":"OG002","value":"-4.67","spread":"17.934"},{"groupId":"OG003","value":"0.40","spread":"20.822"},{"groupId":"OG004","value":"-6.71","spread":"20.236"},{"groupId":"OG005","value":"1.03","spread":"19.829"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.46","spread":"24.451"},{"groupId":"OG001","value":"71.53","spread":"24.394"},{"groupId":"OG002","value":"69.67","spread":"24.581"},{"groupId":"OG003","value":"72.23","spread":"24.699"},{"groupId":"OG004","value":"69.02","spread":"24.688"},{"groupId":"OG005","value":"69.53","spread":"25.100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.16","spread":"25.575"},{"groupId":"OG001","value":"-3.30","spread":"24.912"},{"groupId":"OG002","value":"-5.69","spread":"22.184"},{"groupId":"OG003","value":"-2.08","spread":"27.724"},{"groupId":"OG004","value":"-10.76","spread":"34.350"},{"groupId":"OG005","value":"-0.52","spread":"25.780"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.87","spread":"40.653"},{"groupId":"OG001","value":"65.57","spread":"40.015"},{"groupId":"OG002","value":"62.86","spread":"42.715"},{"groupId":"OG003","value":"62.61","spread":"41.280"},{"groupId":"OG004","value":"60.29","spread":"41.393"},{"groupId":"OG005","value":"64.26","spread":"41.854"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"49.950"},{"groupId":"OG001","value":"0.47","spread":"43.513"},{"groupId":"OG002","value":"-12.22","spread":"42.532"},{"groupId":"OG003","value":"4.17","spread":"44.656"},{"groupId":"OG004","value":"-13.18","spread":"42.501"},{"groupId":"OG005","value":"-3.55","spread":"48.769"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.01","spread":"19.818"},{"groupId":"OG001","value":"66.24","spread":"19.060"},{"groupId":"OG002","value":"65.42","spread":"17.658"},{"groupId":"OG003","value":"65.15","spread":"19.233"},{"groupId":"OG004","value":"62.30","spread":"17.347"},{"groupId":"OG005","value":"63.61","spread":"18.414"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"19.715"},{"groupId":"OG001","value":"2.31","spread":"18.095"},{"groupId":"OG002","value":"-3.91","spread":"19.897"},{"groupId":"OG003","value":"2.33","spread":"17.524"},{"groupId":"OG004","value":"-0.29","spread":"21.989"},{"groupId":"OG005","value":"-2.06","spread":"20.066"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.40","spread":"11.130"},{"groupId":"OG001","value":"45.63","spread":"10.272"},{"groupId":"OG002","value":"45.13","spread":"10.932"},{"groupId":"OG003","value":"45.31","spread":"10.907"},{"groupId":"OG004","value":"44.00","spread":"10.702"},{"groupId":"OG005","value":"45.03","spread":"10.642"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"12.415"},{"groupId":"OG001","value":"0.87","spread":"10.028"},{"groupId":"OG002","value":"-2.55","spread":"10.328"},{"groupId":"OG003","value":"1.97","spread":"10.657"},{"groupId":"OG004","value":"-2.59","spread":"12.895"},{"groupId":"OG005","value":"0.08","spread":"10.328"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.53","spread":"9.884"},{"groupId":"OG001","value":"44.44","spread":"10.048"},{"groupId":"OG002","value":"43.74","spread":"9.739"},{"groupId":"OG003","value":"43.56","spread":"10.267"},{"groupId":"OG004","value":"43.68","spread":"10.359"},{"groupId":"OG005","value":"43.15","spread":"10.091"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"9.373"},{"groupId":"OG001","value":"-1.94","spread":"10.532"},{"groupId":"OG002","value":"-2.29","spread":"8.929"},{"groupId":"OG003","value":"-3.25","spread":"9.998"},{"groupId":"OG004","value":"-2.70","spread":"8.860"},{"groupId":"OG005","value":"-1.59","spread":"10.765"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384","description":"The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) \"no problems\", (2) \"some problems\", or (3) \"severe problems\". A positive change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.210"},{"groupId":"OG001","value":"0.73","spread":"0.222"},{"groupId":"OG002","value":"0.72","spread":"0.223"},{"groupId":"OG003","value":"0.71","spread":"0.244"},{"groupId":"OG004","value":"0.71","spread":"0.246"},{"groupId":"OG005","value":"0.72","spread":"0.189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.251"},{"groupId":"OG001","value":"0.00","spread":"0.233"},{"groupId":"OG002","value":"-0.07","spread":"0.269"},{"groupId":"OG003","value":"0.00","spread":"0.249"},{"groupId":"OG004","value":"-0.04","spread":"0.253"},{"groupId":"OG005","value":"-0.03","spread":"0.241"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384","description":"The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents \"worst imaginable health state\" and 100 represents \"best imaginable health state\". A positive change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.97","spread":"18.460"},{"groupId":"OG001","value":"70.48","spread":"19.993"},{"groupId":"OG002","value":"70.40","spread":"17.630"},{"groupId":"OG003","value":"69.44","spread":"19.907"},{"groupId":"OG004","value":"66.80","spread":"18.846"},{"groupId":"OG005","value":"69.07","spread":"20.094"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"19.631"},{"groupId":"OG001","value":"-1.67","spread":"18.855"},{"groupId":"OG002","value":"-7.24","spread":"18.419"},{"groupId":"OG003","value":"-3.17","spread":"22.003"},{"groupId":"OG004","value":"-1.71","spread":"25.330"},{"groupId":"OG005","value":"-4.11","spread":"16.270"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Function Test Scores at Week 384","description":"Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":"7.95"},{"groupId":"OG001","value":"55.0","spread":"7.84"},{"groupId":"OG002","value":"55.1","spread":"7.26"},{"groupId":"OG003","value":"54.8","spread":"7.12"},{"groupId":"OG004","value":"54.3","spread":"8.26"},{"groupId":"OG005","value":"55.0","spread":"6.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.76"},{"groupId":"OG001","value":"-1.9","spread":"6.81"},{"groupId":"OG002","value":"-1.4","spread":"8.48"},{"groupId":"OG003","value":"-1.2","spread":"7.53"},{"groupId":"OG004","value":"-1.6","spread":"8.05"},{"groupId":"OG005","value":"-0.7","spread":"5.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"12.17"},{"groupId":"OG001","value":"32.6","spread":"11.76"},{"groupId":"OG002","value":"32.4","spread":"11.42"},{"groupId":"OG003","value":"32.3","spread":"11.99"},{"groupId":"OG004","value":"31.8","spread":"12.36"},{"groupId":"OG005","value":"31.7","spread":"12.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"10.77"},{"groupId":"OG001","value":"-3.3","spread":"10.43"},{"groupId":"OG002","value":"-1.5","spread":"11.77"},{"groupId":"OG003","value":"-4.9","spread":"11.14"},{"groupId":"OG004","value":"-4.0","spread":"11.90"},{"groupId":"OG005","value":"-2.1","spread":"9.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"12.45"},{"groupId":"OG001","value":"24.2","spread":"12.28"},{"groupId":"OG002","value":"23.8","spread":"12.11"},{"groupId":"OG003","value":"23.7","spread":"12.96"},{"groupId":"OG004","value":"23.4","spread":"11.76"},{"groupId":"OG005","value":"22.2","spread":"13.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"13.39"},{"groupId":"OG001","value":"-6.0","spread":"11.77"},{"groupId":"OG002","value":"-4.1","spread":"13.04"},{"groupId":"OG003","value":"-7.4","spread":"12.42"},{"groupId":"OG004","value":"-6.7","spread":"13.78"},{"groupId":"OG005","value":"-5.0","spread":"12.74"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":279,"n":868},"commonTop":["Multiple sclerosis relapse","Nasopharyngitis","Urinary tract infection","Flushing","Upper respiratory tract infection"]}}}